Fermenta Biotech Ltd (FERMENTA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Fermenta Biotech Ltd on NSE and BSE, with an AI summary of each filing.
FERMENTA BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
To consider and approve the unaudited financial results (standalone and consolidated) for the period ended September 30, 2026.
Intimation · 05 Nov 2026, 5:30 am
Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve unaudited financial results ....
Intimation · 05 Nov 2026, 5:30 am
Fermenta Biotech Schedules Board Meeting on 5th Nov'26 for Q2 Financial Results Fermenta Biotech Limited has announced that its Board of Directors will meet on 5th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company securities, closed since 1st Oct'26, will remain shut for designated persons, insiders, and connected entities until 48 hours following the declaration of the financial results.
Intimation of investor(s) meeting to be held on October 15, 2026.
Intimation · 13 Oct 2026, 2:52 am
Fermenta Biotech Schedules Physical Group Investor Meeting at Dahej Fermenta Biotech Limited announced that its officials will participate in a physical group investor meeting on 15th Oct'26 in Dahej, Gujarat. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the discussions will be based on publicly available press releases and investor presentations accessible on the company's website and stock exchanges. The company confirmed that no unpublished price sensitive information (UPSI) will be discussed during the interaction.
Intimation of investor(s) meeting(s) to be held on October 14, 2026.
Intimation · 09 Oct 2026, 8:11 pm
Fermenta Biotech Schedules Physical One-to-One Investor Meetings in Mumbai Fermenta Biotech Limited announced that its officials will participate in physical, one-to-one meetings with three individual investors on 14th Oct'26 in Mumbai. The company confirmed that discussions will be limited to publicly available press releases and investor presentations already shared on stock exchanges and its website, with no unpublished price-sensitive information being discussed.
Intimation of investor(s) meeting to be held on October 07, 2026.
Intimation · 01 Oct 2026, 10:47 pm
Fermenta Biotech Schedules Physical One-on-One Investor Meeting on 7th Oct'26 Fermenta Biotech Limited announced that its officials will participate in a physical one-on-one investor meeting in Mumbai on 7th Oct'26. The company stated that discussions will be based on publicly available press releases and investor presentations accessible via stock exchanges and its website, with no unpublished price-sensitive information (UPSI) intended to be shared during the interaction.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Preeti Thakkar
Acquisition/ Disposal of Shares · 30 Sept 2026, 4:45 pm
Promoter Preeti Thakkar Sells 3.96% Stake in Fermenta Biotech Fermenta Biotech Limited promoter Preeti Thakkar sold 11,65,938 equity shares, representing a 3.96% stake in the company, via open market transactions on 28th Sep'26. Following the disposal, her equity holding decreased from 22,40,376 shares (7.61% of total share capital) to 10,74,438 shares (3.65% of total share capital). The company's total voting capital remains unchanged at 2,94,30,987 equity shares.
Intimation of investor meeting to be held on October 5, 2026.
Intimation · 29 Sept 2026, 10:31 pm
Fermenta Biotech Schedules Physical One-on-One Investor Meeting on 5th Oct'26 Fermenta Biotech Limited announced under Regulation 30 of SEBI (LODR) Regulations, 2015, that company officials will participate in a physical, one-to-one investor meeting in Mumbai on 5th Oct'26. The discussions will center on publicly available press releases and investor presentations accessible via the company’s website and stock exchanges. Fermenta confirmed that no unpublished price-sensitive information (UPSI) will be shared during the interaction.
Intimation of investor(s) meeting.
Intimation · 24 Sept 2026, 9:22 pm
Fermenta Biotech Schedules Physical One-on-One Investor Meeting Fermenta Biotech Limited announced that its officials will participate in a physical, one-to-one investor meeting scheduled for 29th Sep'26 in Mumbai. The company confirmed that discussions will rely strictly on publicly available investor presentations and press releases, with no unpublished price-sensitive information (UPSI) to be shared during the interaction.
Intimation of investor(s) meeting.
Intimation · 22 Sept 2026, 2:38 am
Fermenta Biotech Schedules Physical One-to-One Investor Meeting in Mumbai Fermenta Biotech Limited has announced that company officials will participate in a physical, one-to-one investor meeting scheduled for 24th Sep'26 in Mumbai. The company confirmed that discussions will rely strictly on publicly available investor presentations and press releases, with no unpublished price-sensitive information (UPSI) intended to be shared during the interaction.
Intimation of investor(s) meet.
Intimation · 17 Sept 2026, 9:37 pm
Fermenta Biotech Schedules One-on-One Physical Investor Meeting in Mumbai Fermenta Biotech Limited announced that its officials will participate in a physical, one-to-one investor meeting in Mumbai on 22nd Sep'26, pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. The discussions will center on publicly available press releases and investor presentations hosted on the company and stock exchange websites, with no unpublished price sensitive information (UPSI) intended to be shared.
Dispatch of Letters to shareholders regarding transfer of Equity Shares of the Company to the Investor Education and Protection Fund (''IEPF'') account.
Others (Uncategorized) · 16 Sept 2026, 9:14 pm
Fermenta Biotech Notices IEPF Share Transfer for Unclaimed Dividends Fermenta Biotech has dispatched notices on 16th Sep'26 to shareholders with unclaimed dividends for seven consecutive years starting from the FY19-20 interim dividend. Under Section 124(6) of the Companies Act, 2013, concerned investors must claim their unpaid dividends on or before 18th Nov'26. Failing to do so will result in the company transferring the corresponding equity shares and unclaimed amounts to the demat account of the Investor Education and Protection Fund (IEPF) Authority.
Press Release regarding exclusive Licence Agreement with Vellore Institute of Technology (''VIT''), Vellore for Vitamin B12 Fortification Technology.
Press Release · 08 Sept 2026, 10:34 pm
Fermenta Biotech Signs Exclusive License Agreement with VIT for Vitamin B12 Fortification Fermenta Biotech signed an exclusive license agreement on 8th Sep'26 with Vellore Institute of Technology (VIT) to commercialize patent-pending technology (Indian Patent Application No. 202441015300) for natural in-situ Vitamin B12 fortification in fermented foods. The process enriches Vitamin B12 directly during fermentation—applicable to curd, batters, and breads—integrating seamlessly with existing manufacturing methods and retaining ~80% Vitamin B12 post-cooking. Fermenta aims to scale this innovation across FMCG, food and nutrition, and nutraceutical segments, advancing application development, regulatory evaluations, and commercial solutions.
Intimation of investor(s) meeting(s) to be held on September 3, 2026.
Intimation · 27 Aug 2026, 9:30 pm
Fermenta Biotech Announces Investor Meeting Fermenta Biotech will conduct one-to-one investor meetings on 03 Sep'26. The physical meetings will be held in Mumbai. The company confirmed that discussions will be based on information already available in public press releases and investor presentations. Fermenta also stated that no unpublished price sensitive information (UPSI) will be disclosed during these interactions.
Intimation of investor meeting to be held on August 21, 2026.
Intimation · 17 Aug 2026, 10:18 pm
Fermenta Biotech Announces Investor Meeting in Mumbai Fermenta Biotech Limited (FERMENTA) has scheduled a one-to-one investor meeting on 21 Aug'26. The physical meeting will be held in Mumbai with company officials. Discussions will be based on publicly available information, such as press releases and investor presentations available on the company website. FERMENTA has stated that no unpublished price-sensitive information (UPSI) will be disclosed during the interaction. The schedule is subject to potential changes.
Revision in credit rating.
Others (Uncategorized) · 17 Aug 2026, 10:10 pm
Fermenta Biotech Receives Credit Rating Upgrade from CARE On 17 Aug'26, CARE Ratings upgraded Fermenta Biotech's long-term bank facilities to 'CARE BBB+; Stable' from 'CARE BBB; Stable', with the facility size enhanced to ₹166.73 crore from ₹118.94 crore. Additionally, short-term bank facilities of ₹6.25 crore were upgraded to 'CARE A2' from 'CARE A3+'. The upgrades signal an improved credit profile and financial stability for the company, positively impacting its borrowing costs and capacity. Total rated facilities now stand at ₹172.98 crore.
Declaration of voting results of the 74th Annual General Meeting.
Annual General Meeting · 12 Aug 2026, 4:42 am
Scrutinizers report of 74th Annual General Meeting.
Annual General Meeting · 12 Aug 2026, 4:34 am
Outcome of 74th Annual General Meeting.
Annual General Meeting · 12 Aug 2026, 4:30 am
Presentation for shareholders at 74th Annual General Meeting (''AGM'')
Annual General Meeting · 11 Aug 2026, 8:07 pm
Earnings presentation - Q1/FY27
Investor Presentation · 11 Aug 2026, 7:17 pm
Fermenta Biotech Q1FY27 Revenue Flat QoQ; Profit Down on Weak Animal Nutrition Fermenta Biotech reported Q1FY27 revenue of ₹126.2 crore, flat QoQ but down 13% YoY due to a high base with non-recurring income in Q1FY26. Profit after tax declined 56% YoY to ₹9.5 crore. The human nutrition segment showed strong sequential performance, with revenue up 24% QoQ to ₹76.5 crore. However, animal nutrition remained a weak spot, with revenue down 45% QoQ and 41% YoY. India's contribution to revenue strengthened, rising to 47% from 35% a year earlier, reflecting strong domestic demand.
Press release regarding unaudited financial results of Q1FY27.
Press Release · 11 Aug 2026, 7:07 pm
Fermenta Biotech Q1FY27 Net Profit Plummets 56% Amid Weak Animal Nutrition Pricing Fermenta Biotech reported Q1FY27 consolidated net profit of INR 9.5 crore, down 56% YoY and 49% QoQ. Revenue was INR 126.2 crore, down 13% YoY and flat QoQ. EBITDA fell 39% YoY to INR 22.4 crore. The sharp YoY decline was attributed to an exceptionally strong base quarter and a 40% fall in Vitamin D3 Animal Nutrition realisations. Human Nutrition revenue was down 10% YoY but grew 24% QoQ. The India market's revenue contribution increased to 47% from 35% a year earlier.
Unaudited financial results for quarter ended June 30, 2026.
Financial Result · 11 Aug 2026, 6:56 pm
Fermenta Biotech Q1 FY27 Net Profit Declines Amid Lower Revenue Fermenta Biotech reported a consolidated net profit of ₹9.53 Cr for Q1 FY27, a 55.9% YoY and 48.8% QoQ decline. Revenue from operations fell 10.6% YoY to ₹121.82 Cr. The core Bulk Drugs/Chemicals segment revenue decreased 12.3% YoY to ₹117.39 Cr. EBITDA stood at ₹22.43 Cr, down 42.1% YoY, with margins contracting significantly to 18.4% from 27.6% in Q1 FY26. Standalone net profit for the quarter was ₹14.99 Cr, down 7.7% YoY. Basic EPS on a consolidated basis was ₹3.40.
Outcome of Board meeting and unaudited financial results - June 30, 2026.
Outcome · 11 Aug 2026, 6:48 pm
Fermenta Biotech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) ■ Revenue: 12,182 (-10.6% YoY | +0.2% QoQ) ■ EBITDA: 1,805 (-36.1% YoY | -9.7% QoQ) ■ EBITDA Margin (%): 14.8 (-590 bps YoY | -163 bps QoQ) ■ PAT: 974 (-55.4% YoY | -49.3% QoQ) ■ EPS (INR): 3.34 (-55.3% YoY | -4.0% QoQ) Fermenta Biotech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) Segmental Performance Bulk drugs/chemicals ■ Revenue: 11,739 (-12.3% YoY | -5.3% QoQ) ■ EBIT: 1,905 (-30.8% YoY | -7.2% QoQ) ■ EBIT Margin (%): 16.2 (-433 bps YoY | -33 bps QoQ) Property ■ Revenue: 199 (-43.9% YoY | +5.8% QoQ) ■ EBIT: 6.8 (-95.6% YoY | -69.2% QoQ) ■ EBIT Margin (%): 3.4 (-4075 bps YoY | -836 bps QoQ)
Intimation of investor(s) meeting(s).
Intimation · 11 Aug 2026, 1:42 am
Fermenta Biotech to Hold One-on-One Investor Meeting Fermenta Biotech Limited will hold a physical one-on-one investor meeting in Mumbai on 17 Aug'26. Company officials will participate in the interaction. The discussions will be based on publicly available information, such as press releases and investor presentations, and the company confirmed that no unpublished price sensitive information (UPSI) will be disclosed. The meeting schedule is subject to potential changes.